VTYX - NASDAQ
Ventyx Biosciences, Inc.
$14.00
+0.0000%Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
At a Glance
Live SnapshotVentyx Biosciences, Inc. Management Team
Dr. Mark S. Forman M.D., Ph.D.
Chief Medical Officer
Compensation
$380,965
Mr. Matthew Richard Moore
Chief Operating Officer
Compensation
$612,510
Dr. John M. Nuss Ph.D.
Chief Scientific Officer
Compensation
$630,635
Dr. Sheila K. Gujrathi M.D.
Executive Chairperson
Compensation
$125,000
Dr. Raju S. Mohan Ph.D.
Founder, Chief Executive Officer, President & Director
Compensation
$979,215
Ms. Snehal Naik Ph.D.
Senior Vice President of Clinical Development
Mr. Roy M. Gonzales CPA, M.B.A.
Senior Vice President of Finance and Principal Financial & Accounting Officer
Ms. Rosa Ferrao
Senior Vice President of Regulatory Affairs
Ms. Kathy Ogilvie Ph.D.
Senior Vice President of Translational & Nonclinical Research
Ventyx Biosciences, Inc. Insider Positioning
During the last 12 months, insiders have purchased $450K and sold $463K worth of VTYX shares, resulting in $13K of net selling activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
60.0K
463.30K
-463K
-$463K
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
200.0K
450.00K
0
0.00
+450K
+$450K
Top Buyers
Subramaniam Somu
Director
$90K
White William Richard
Director
$90K
Gujrathi Sheila
Director
$90K
Cadoret-Manier Onaiza
Director
$90K
Hulme Allison
Director
$90K
Top Sellers
Mohan Raju
Director, Officer: Ceo And President
$365K
Nuss John
Officer: Chief Scientific Officer
$98K
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $13K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Insider Participation
5 insider buyers vs. 2 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Balanced insider activity: Roughly equal buying and selling suggests normal portfolio management rather than strong directional signals. Look to other metrics for clearer investment insights.
SEC Filings
VTYX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 23, 2025 | June 04, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 25, 2024 | June 05, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 26, 2023 | June 07, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 27, 2022 | June 08, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.